Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

Bristol Myers Squibb, 2seventy bio to discontinue enrollment in phase 3 KarMMa-9 study of Abecma in patients with newly diagnosed MM: Princeton, New Jersey Friday, September 27, 2 ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Investors have circled back to healthcare stocks this year, and they’re likely to stick around. If they came for the ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by ...

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

The target of the strike in Lebanon was the group’s leader, Hassan Nasrallah, according to Israeli and American officials. The attack came shortly after the Israeli prime minister gave a defiant ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...